AVX001外用治疗轻中度斑块状银屑病的首次人体随机对照试验
本随机、双盲、安慰剂对照、分侧设计的首次人体(0期)研究纳入94例轻中度斑块状银屑病患者,评估cPLA2α抑制剂AVX001(0.002%–5.0%)的外用安全性及对mPASI的疗效。结果显示AVX001安全,无3–4级局部皮肤反应不良事件;5%剂量组第4周mPASI降低29%,3%与5%联合事后分析mPASI降低31%(P=0.058),浸润显著改善(P=0.036)。
要点
- AVX001外用至5%剂量安全耐受,无3–4级局部皮肤反应不良事件。
- 5%剂量组第4周mPASI降低29%,3%与5%联合事后分析降低31%(P=0.058)。
- 3%与5%联合事后分析显示浸润显著改善(P=0.036)。
核心结论
- AVX001外用至5%剂量耐受良好,并显示出安慰剂校正后达统计学显著水平的临床效果。
- 治疗期间mPASI持续改善,提示延长治疗可能获得更优疗效。
研究设计与样本
- 随机、双盲、安慰剂对照、分侧设计的首次人体(0期)研究,纳入94例轻中度斑块状银屑病男性患者,88例完成AVX001与安慰剂治疗。
- 治疗期4周,随访2周,于筛选、随机化及每周评估一次;AVX001与安慰剂盲法每日一次外用于对称受累区域。
主要发现
- AVX001安全,未出现3–4级局部皮肤反应不良事件。
- 5%剂量组第4周mPASI降低29%。
- 3%与5%联合剂量事后分析显示mPASI降低31%(P=0.058),浸润显著改善(P=0.036)。
- 积极治疗侧在治疗1周后mPASI即见改善,并持续至4周治疗结束。
关键数值与推荐
- 主要目标为评估AVX001 0.002%至5.0%剂量的皮肤安全性与耐受性,安全性以3–4级局部皮肤反应不良事件评估。
- 次要目标为比较AVX001与安慰剂对改良PASI(mPASI)评分的疗效。
临床怎么用
- AVX001 3%–5%外用可作为轻中度斑块状银屑病潜在局部治疗选择,但需更大样本验证。
- 治疗期间mPASI持续改善,提示临床可考虑延长疗程以评估更优疗效。
局限性
- 3%与5%联合剂量分析为事后分析,mPASI降低31%的P值为0.058,未达传统统计学显著水平。
- 研究为0期首次人体试验,样本量有限(94例随机、88例完成),疗效结论需后续研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cytosolic phospholipase A2 (cPLA2α) is an enzyme suggested as a therapeutic target in inflammatory skin diseases. AVX001, a cPLA2α inhibitor, was investigated in a randomized, double-blind, placebo-controlled, split-design, first-in-man study in patients with mild to moderate psoriasis. OBJECTIVES: The primary objective was to evaluate cutaneous safety and tolerability of AVX001 in doses from 0.002% to 5.0%. Safety was assessed as local skin reaction adverse events (LSRAE) grades 3-4. The secondary objective was assessment of efficacy on modified PASI (mPASI) score compared with placebo. METHODS: Of 94 randomized men, 88 completed treatment with AVX001 and placebo. The treatment period was four weeks with two-week follow-up with assessment at screening, randomization and once weekly until study end. AVX001 and placebo were applied blinded at symmetrically affected areas once daily. RESULTS: AVX001 was safe with no grades 3-4 LSRAE. A 29% reduction in mPASI was seen at the 5% dose level at week four. Post hoc analysis of combined doses of 3% and 5% showed a clinical relevant effect with 31% reduction in mPASI (P = 0.058) and statically significant reduction of the infiltration (P = 0.036). The actively treated side showed improvement in mPASI score after one week of treatment, and the observed improvement continued throughout the four weeks of treatment. CONCLUSIONS: Treatment with AVX001 is well tolerated in doses up to 5%, and showed placebo-adjusted, clinical effects at a level of statistical significance. The improvement throughout the treatment period suggests that longer treatment could conceivably result in superior efficacy.
引用
- Omland SH, Habicht A, Damsbo P, et al. A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol. 2017. PMID: 28107559. doi:10.1111/jdv.14128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。